Hermida Ramón C, Mojón Artemio, Fernández José R
Bioengineering & Chronobiology Laboratories; Atlantic Research Center for Information and Communication Technologies (atlanTTic), University of Vigo , Vigo, Spain.
Chronobiol Int. 2020 Aug;37(8):1270-1272. doi: 10.1080/07420528.2020.1812898. Epub 2020 Sep 1.
The purpose of this communication is to respond to the continuing invalid criticism by Lemmer and Middeke of the MAPEC and Hygia Chronotherapy Trial by emphasizing the: (i) already unambiguously reported ambulatory blood pressure monitoring (ABPM)-based definition of hypertension utilized as inclusion criterion of both investigations and (ii) impact of bedtime hypertension chronotherapy on ABPM-assessed parameters and cardiovascular disease (CVD) outcome for participants further categorized by influential markers of CVD risk. In so doing, we call attention to apparent unethical misconduct of Lemmer and Middeke of multiple duplicated publications of the very same unfounded criticisms.
本通讯的目的是回应莱默和米德克对MAPEC和希吉亚时间疗法试验持续存在的无效批评,强调:(i) 两项研究均已明确报告将基于动态血压监测(ABPM)的高血压定义用作纳入标准,以及 (ii) 睡前高血压时间疗法对按心血管疾病(CVD)风险影响因素进一步分类的参与者的ABPM评估参数和心血管疾病(CVD)结局的影响。在此过程中,我们提请注意莱默和米德克对同一毫无根据的批评进行多次重复发表的明显不道德行为。